UA138613U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

A method for predicting the development of osteoarthritis, including clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of thrombomodulin, folic acid, glycosaminoglycans (GAG), C-reactive protein (SRP), interleukin 6 (IL-6), homocystoma SS, levels of thrombomodulin> 5 ng / ml, folic acid <6 ng / ml, GAG> 28 μmol / l, PSA> 6 mg / l, IL-6> 10 ng / l, homocysteine> 20 μmol / l predict the development of osteoarthritis .

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies TSA.N.

Okorokov Diagnosis of diseases of internal organs. M., 2001. - vol. 2. - pp. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (6eMOb5 17860), the content of thrombomodulin, folic acid, glycosaminoglycans (GAG), C-reactive protein (CRP), interleukin 6 ( IL-6), homocysteine and with homozygous carrier 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, GAG "28 μmol/l, SRP "6b mg/l, IL-6 "10 ng /l, homocysteine »20 μmol/l predict the development of osteoarthritis.

Application of the method. Upon admission, the patient is examined, X-rays are taken, the polymorphism of the eMO5 1786C gene is determined, the content of thrombomodulin, folic acid, GAG, SRP, IL-b6, homocysteine is determined by the immunoenzymatic method. With homozygous carrier 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, GAG "28 μmol/l, SRP "b mg/l, IL-6 510 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method.

Patient V., 68 years old, was admitted to the clinic due to pain in the right hip joint. Examined, x-ray taken. No signs of osteoarthritis were found. The eMO5 1786C gene polymorphism and the content of thrombomodulin, folic acid, GAG, SRP, IL-6, and homocysteine were determined in the blood serum. A homozygous carrier of 786-SS was established, the levels of thrombomodulin - 12 ng/ml, folic acid - 3.2 ng/ml, GAG - 45 μmol/l, SRP - 18 mg/l, IL-6-26 ng/l, homocysteine - 33 μmol/l. Diagnosed development

From osteoarthritis. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, in which a clinical examination and radiography are performed, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (eMmo5 T786C), the content of thrombomodulin, folic acid, glycosaminoglycans (GAG), C-reactive protein ( SRP), interleukin 6 (IL-6), homocysteine and with homozygous carrier 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, GAG "28 μmol/l, SRP "6 mg/l, IL-6 »10 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.